Therapeutic approaches to cholinergic deficiency in Lewy body diseases

References

• Litvan I, Aarsland D, Adler CH, et al. MDS task force on mild cognitive impairment in Parkinson’s Disease: critical review of PD-MCI. Mov.Disord. 2011;26:1814–1824.
   PubMed Web of Science ®Google Scholar
• McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy Bodies: 4th consensus report of the DLB consortium. Neurology. 2017;89:88–100.
   PubMed Web of Science ®Google Scholar
• Fereshtehnejad SM, Yao C, Pelletier A, et al. Evolution of prodromal Parkinson’s disease and dementia with Lewy Bodies: a prospective study. Brain. 2019;142:2051–2067.
   PubMed Web of Science ®Google Scholar
• Haba-Rubio J, Frauscher B, Marques-Vidal P, et al. Prevalence and determinants of REM sleep behavior disorder in the general population. Sleep. 2017 Dec 5. [Epub ahead of print].
   Google Scholar
• Postuma RB, Gagnon JF, Tuineaig M, et al. Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal? Sleep. 2013;36:1579–1585.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhou P, Yuan T. The cholinergic system in the cerebellum: from structure to function. Rev.Neurosci. 2016;27:769–776.
   PubMed Web of Science ®Google Scholar
• Bigl V, Woolf NJ, Butcher LL. Cholinergic projections from the basal forebrain to frontal, parietal, temporal, occipital, and cingulate cortices: a combined fluorescent tracer and acetylcholinesterase analysis. Brain ResBull. 1982;8:727–749.
   PubMed Web of Science ®Google Scholar
• Mesulam MM, Mufson EJ, Levey AI, et al. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (Substantia Innominata), and hypothalamus in the rhesus monkey. J.Comp.Neurol. 1983;214:170–197.
   PubMed Web of Science ®Google Scholar
• Mesulam MM, Mufson EJ, Wainer BH, et al. Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience. 1983;10:1185–1201.
   PubMed Web of Science ®Google Scholar
• Lewy FH. Zur Pathologischen Anatomie Der Paralysis Agitans. Dtsch Ztschr Nervenheilkunde. 1914;50:50–55.
   Google Scholar
• Gaspar P, Gray F. Dementia in idiopathic Parkinson’s Disease. A neuropathological study of 32 cases. Acta Neuropathol. 1984;64:43–52.
   PubMed Web of Science ®Google Scholar
• Nakano I, Hirano A. Parkinson’s Disease: neuron loss in the nucleus basalis without concomitant Alzheimer’s disease. Ann.Neurol. 1984;15:415–418.
   PubMed Web of Science ®Google Scholar
• Arendt T, Bigl V, Arendt A, et al. Loss of neurons in the nucleus basalis of meynert in Alzheimer’s Disease, paralysis agitans and Korsakoff’s Disease. Acta Neuropathol. 1983;61:101–108.
   PubMed Web of Science ®Google Scholar
• Whitehouse PJ, Hedreen JC, White CL 3rd, et al. Basal forebrain neurons in the dementia of Parkinson Disease. Ann.Neurol. 1983;13:243–248.
   PubMed Web of Science ®Google Scholar
• Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson’s Disease: comparisons with Alzheimer’s Disease. J.Neurol.Neurosurg.Psychiatry. 1985;48:413–421.
   PubMed Web of Science ®Google Scholar
• Candy JM, Perry RH, Perry EK, et al. Pathological changes in the nucleus of meynert in Alzheimer’s and Parkinson’s Diseases. J.Neurol.Sci. 1983;59:277–289.
   PubMed Web of Science ®Google Scholar
• Perry EK, Irving D, Kerwin JM, et al. Cholinergic transmitter and neurotrophic activities in Lewy Body dementia: similarity to Parkinson’s and distinction from Alzheimer Disease. Alzheimer DisAssocDisord. 1993;7:69–79.
   PubMed Web of Science ®Google Scholar
• Tiraboschi P, Hansen LA, Alford M, et al. Cholinergic dysfunction in diseases with Lewy Bodies. Neurology. 2000;54:407–411.
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in Parkinsonian Dementia than in Alzheimer Disease: an in vivo positron emission tomographic study. Arch.Neurol. 2003;60:1745–1748.
   PubMed Web of Science ®Google Scholar
• Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson Disease: functional imaging of cholinergic and dopaminergic pathways. Neurology. 2005;65:1716–1722.
   PubMed Web of Science ®Google Scholar
• Shimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy Body disease by PET. Neurology. 2009;73:273–278.
   PubMed Web of Science ®Google Scholar
• Tokimura H, Di Lazzaro V, Tokimura Y, et al. Short latency inhibition of human hand motor cortex by somatosensory input from the hand. J.Physiol. 2000;523 Pt(2):503–513.
   Web of Science ®Google Scholar
• Cromarty RA, Elder GJ, Graziadio S, et al. Neurophysiological biomarkers for Lewy Body dementias. Clin.Neurophysiol. 2016;127:349–359.
   PubMed Web of Science ®Google Scholar
• Di Lazzaro V, Oliviero A, Profice P, et al. Muscarinic receptor blockade has differential effects on the excitability of intracortical circuits in the human motor cortex. ExpBrain Res. 2000;135:455–461.
   PubMed Web of Science ®Google Scholar
• Yarnall AJ, Rochester L, Baker MR, et al. Short latency afferent inhibition: a biomarker for mild cognitive impairment in Parkinson’s Disease? Mov.Disord. 2013;28:1285–1288.
   PubMed Web of Science ®Google Scholar
• Celebi O, Temucin CM, Elibol B, et al. Short latency afferent inhibition in Parkinson’s Disease patients with dementia. Mov.Disord. 2012;27:1052–1055.
   PubMed Web of Science ®Google Scholar
• Di Lazzaro V, Pilato F, Dileone M, et al. Functional evaluation of cerebral cortex in dementia with Lewy Bodies. Neuroimage. 2007;37:422–429.
   PubMed Web of Science ®Google Scholar
• Oikawa H, Sasaki M, Ehara S, et al. Substantia innominata: MR findings in Parkinson’s Disease. Neuroradiology. 2004;46:817–821.
   PubMed Web of Science ®Google Scholar
• Choi SH, Jung TM, Lee JE, et al. Volumetric analysis of the substantia innominata in patients with Parkinson’s Disease according to cognitive status. Neurobiol.Aging. 2012;33:1265–1272.
   PubMed Web of Science ®Google Scholar
• Lee JE, Cho KH, Song SK, et al. Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson’s Disease. J Neurol Neurosurg Psychiatry. 2014;85:7–16.
   PubMed Web of Science ®Google Scholar
• Zaborszky L, Hoemke L, Mohlberg H, et al. Stereotaxic probabilistic maps of the magnocellular cell groups in human basal forebrain. Neuroimage. 2008;42:1127–1141.
   PubMed Web of Science ®Google Scholar
• Ray NJ, Bradburn S, Murgatroyd C, et al. In vivo cholinergic basal forebrain atrophy predicts cognitive decline in De Novo Parkinson’s Disease. Brain. 2018;141:165–176.
   PubMed Web of Science ®Google Scholar
• Schulz J, Pagano G, Fernandez Bonfante JA, et al. Nucleus basalis of meynert degeneration precedes and predicts cognitive impairment in Parkinson’s Disease. Brain. 2018;141:1501–1516.
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson’s Disease and Parkinsonian dementia. J.Neurol. 2006;253:242–247.
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Albin RL, Muller ML, et al. Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson Disease and evidence of interaction effects. JAMA Neurol. 2015;72:194–200.
   PubMed Web of Science ®Google Scholar
• Barrett MJ, Sperling SA, Blair JC, et al. Lower Volume, more impairment: reduced cholinergic basal forebrain grey matter density is associated with impaired cognition in Parkinson Disease. J.Neurol.Neurosurg.Psychiatry. 2019.
   PubMed Web of Science ®Google Scholar
• Shinotoh H, Namba H, Yamaguchi M, et al. Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson’s Disease and progressive supranuclear palsy. Ann.Neurol. 1999;46:62–69.
   PubMed Web of Science ®Google Scholar
• Manganelli F, Vitale C, Santangelo G, et al. Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson’s Disease. Brain. 2009;132:2350–2355.
   PubMed Web of Science ®Google Scholar
• Barrett MJ, Blair JC, Sperling SA, et al. Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson Disease. Neurology. 2018;90:e1618–e1626.
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Kaufer DI, Hendrickson R, et al. Cortical cholinergic denervation is associated with depressive symptoms in Parkinson’s Disease and Parkinsonian Dementia. J.Neurol.Neurosurg.Psychiatry. 2007;78:641–643.
   PubMed Web of Science ®Google Scholar
• McKeith I, Del Ser T, Spano P, et al. Efficacy of Rivastigmine in dementia with Lewy Bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356:2031–2036.
   PubMed Web of Science ®Google Scholar
• Fabbrini G, Barbanti P, Aurilia C, et al. Donepezil in the treatment of hallucinations and delusions in Parkinson’s Disease. Neurol.Sci. 2002;23:41–43.
   PubMed Web of Science ®Google Scholar
• Kurita A, Ochiai Y, Kono Y, et al. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson’s Disease. JGeriatrPsychiatry Neurol. 2003;16:184–188.
   PubMed Web of Science ®Google Scholar
• Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s Disease. Clin.Neuropharmacol. 2002;25:107–110.
   PubMed Web of Science ®Google Scholar
• Reading PJ, Luce AK, McKeith IG. Rivastigmine in the Treatment of Parkinsonian Psychosis and Cognitive Impairment: preliminary findings from an open trial. Mov.Disord. 2001;16:1171–1174.
   PubMed Web of Science ®Google Scholar
• Rovers JM, Dautzenberg PL, Bruggen JPT. Rivastigmine as adjunctive therapy in the therapeutic dilemma for the treatment of hallucinations due to Parkinson Disease]. Tijdschr.Gerontol.Geriatr. 2006;37:117–120.
   PubMedGoogle Scholar
• Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s Disease. Mov.Disord. 2006;21:1899–1907.
   PubMed Web of Science ®Google Scholar
• Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s Disease: a case series. Curr.Med.Res.Opin. 2002;18:258–264.
   PubMed Web of Science ®Google Scholar
• Devos D, Moreau C, Maltete D, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson’s Disease: a double-blind, placebo-controlled, randomised clinical trial. J.Neurol.Neurosurg.Psychiatry. 2014;85:668–674.
   PubMed Web of Science ®Google Scholar
• Lemstra AW, Eikelenboom P, van Gool WA. The cholinergic deficiency syndrome and its therapeutic implications. Gerontology. 2003;49:55–60.
   PubMed Web of Science ®Google Scholar
• Pinto T, Lanctot KL, Herrmann N. Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer’s Type. Ageing ResRev. 2011;10:404–412.
   Google Scholar
• Bohnen NI, Frey KA, Studenski S, et al. Gait speed in Parkinson Disease correlates with cholinergic degeneration. Neurology. 2013;81:1611–1616.
   PubMed Web of Science ®Google Scholar
• Rochester L, Yarnall AJ, Baker MR, et al. Cholinergic dysfunction contributes to gait disturbance in early Parkinson’s Disease. Brain. 2012;135:2779–2788.
   PubMed Web of Science ®Google Scholar
• Chung KA, Lobb BM, Nutt JG, et al. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson Disease. Neurology. 2010;75:1263–1269.
   PubMed Web of Science ®Google Scholar
• Henderson EJ, Lord SR, Brodie MA, et al. Rivastigmine for gait stability in patients with Parkinson’s Disease (ReSPonD): a randomised, double-blind, placebo-controlled, Phase 2 trial. Lancet Neurol. 2016;15:249–258.
   PubMed Web of Science ®Google Scholar
• Li Z, Yu Z, Zhang J, et al. Impact of rivastigmine on cognitive dysfunction and falling in Parkinson’s Disease Patients. Eur.Neurol. 2015;74:86–91.
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Muller ML, Kotagal V, et al. Heterogeneity of cholinergic denervation in Parkinson’s Disease without dementia. JCerebBlood Flow Metab. 2012;32:1609–1617.
   PubMed Web of Science ®Google Scholar
• Saxena M, Dubey R. Target Enzyme in Alzheimer’s Disease: acetylcholinesterase Inhibitors. Curr Top Med Chem. 2019;19:264–275.
   PubMed Web of Science ®Google Scholar
• Chitnis S, Rao J. Rivastigmine in Parkinson’s Disease dementia. Expert Opin Drug Metab Toxicol. 2009;5:941–955.
   PubMed Web of Science ®Google Scholar
• Lilienfeld S. Galantamine–a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s Disease. CNS Drug Rev. 2002;8:159–176.
   PubMedGoogle Scholar
• Goldman JG, Vaughan CL, Goetz CG. An update expert opinion on management and research strategies in Parkinson’s Disease psychosis. Expert OpinPharmacother. 2011;12:2009–2024.
   PubMed Web of Science ®Google Scholar
• Pagano G, Rengo G, Pasqualetti G, et al. Cholinesterase inhibitors for Parkinson’s Disease: a systematic review and meta-analysis. J.Neurol.Neurosurg.Psychiatr. 2015;86:767–773.
   PubMed Web of Science ®Google Scholar
• van Laar T, De Deyn PP, Aarsland D, et al. Effects of cholinesterase inhibitors in Parkinson’s disease dementia: a review of clinical data. CNS Neurosci Ther. 2011;17:428–441.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Ballard C, Rongve A, et al. Clinical trials of dementia with Lewy Bodies and Parkinson’s Disease dementia. Curr Neurol Neurosci Rep. 2012;12:492–501.
   PubMed Web of Science ®Google Scholar
• Stinton C, McKeith I, Taylor JP, et al. Pharmacological management of Lewy Body dementia: a systematic review and meta-analysis. Am.J.Psychiatry. 2015;172:731–742.
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s Disease. N.Engl.J.Med. 2004;351:2509–2518.
   PubMed Web of Science ®Google Scholar
• Emre M, Poewe W, De Deyn PP, et al. Long-term safety of rivastigmine in Parkinson Disease dementia: an open-label, randomized study. Clin.Neuropharmacol. 2014;37:9–16.
   PubMed Web of Science ®Google Scholar
• Emre M, Cummings JL, Lane RM. Rivastigmine in dementia associated with Parkinson’s Disease and Alzheimer’s Disease: similarities and differences. JAlzheimer’s Dis. 2007;11:509–519.
   PubMed Web of Science ®Google Scholar
• Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson’s Disease dementia: a randomized, double-blind efficacy and safety study. Mov.Disord. 2012;27:1230–1238.
   PubMed Web of Science ®Google Scholar
• Beversdorf DQ, Warner JL, Davis RA, et al. Donepezil in the treatment of dementia with Lewy Bodies. Am.J.Geriatr.Psychiatry. 2004;12:542–544.
   PubMed Web of Science ®Google Scholar
• Mori E, Ikeda M, Kosaka K, et al. Donepezil for dementia with Lewy Bodies: a randomized, placebo-controlled trial. Ann.Neurol. 2012;72:41–52.
   PubMed Web of Science ®Google Scholar
• Thomas AJ, Burn DJ, Rowan EN, et al. A comparison of the efficacy of donepezil in Parkinson’s Disease with dementia and dementia with Lewy Bodies. Int.J.Geriatr.Psychiatry. 2005;20:938–944.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson’s Disease with dementia. Int.J.Geriatr.Psychiatry. 2003;18:937–941.
   PubMed Web of Science ®Google Scholar
• Litvinenko IV, Odinak MM, Mogil’naya VI, et al. Efficacy and safety of galantamine (Reminyl) for dementia in patients with Parkinson’s Disease (an Open controlled trial). Neurosci.Behav.Physiol. 2008;38:937–945.
   PubMedGoogle Scholar
• Grace J, Amick MM, Friedman JH. A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson Disease. J.Neurol.Neurosurg.Psychiatr. 2009;80:18–23.
   PubMed Web of Science ®Google Scholar
• Edwards K, Royall D, Hershey L, et al. Efficacy and safety of galantamine in patients with dementia with Lewy Bodies: a 24-week open-label study. Dement.Geriatr.Cogn.Disord. 2007;23:401–405.
   PubMed Web of Science ®Google Scholar
• Seppi K, Ray Chaudhuri K, Coelho M, et al., Sampaio and the collaborators of the Parkinson’s Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders,Society Evidence. Update on treatments for nonmotor symptoms of Parkinson’s Disease-an evidence-based medicine review. Mov.Disord. 2019;34:180–198.
   PubMed Web of Science ®Google Scholar
• Pink J, O’Brien J, Robinson L, et al. Dementia: assessment, management and support: summary of updated NICE guidance. BMJ. 2018;361:k2438.
   PubMedGoogle Scholar
• Sawada H, Oeda T, Kohsaka M, et al. Early use of donepezil against psychosis and cognitive decline in Parkinson’s Disease: a randomised controlled trial for 2 Years. J Neurol Neurosurg. 2018;89:1332–1340.
   PubMed Web of Science ®Google Scholar
• Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer’s Disease. Clin.Pharmacokinet. 2013;52:225–241.
   Web of Science ®Google Scholar
• Medhurst AD, Lezoualc’h F, Fischmeister R, et al. Quantitative mRNA analysis of five C-terminal splice variants of the human 5-HT4 receptor in the central nervous system by taqman real time RT-PCR. Brain ResMolBrain Res. 2001;90:125–134.
   PubMed Web of Science ®Google Scholar
• Varnäs K, Halldin C, Pike VW, et al. Distribution of 5-HT4 receptors in the postmortem human brain--an autoradiographic study using [125I]SB 207710. Eur.Neuropsychopharmacol. 2003;13:228–234.
   PubMed Web of Science ®Google Scholar
• Mohler EG, Shacham S, Noiman S, et al. VRX-03011, a novel 5-HT4 Agonist, enhances memory and hippocampal acetylcholine efflux. Neuropharmacology. 2007;53:563–573.
   PubMed Web of Science ®Google Scholar
• Shen F, Smith JAM, Chang R, et al. 5-HT(4) Receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: a pharmacodynamic and pharmacokinetic assessment. Neuropharmacology. 2011;61:69–79.
   PubMed Web of Science ®Google Scholar
• Megerian JT, Kalafer M, Schacham S, et al. Results of a phase 2A study of a novel 5HT4 agonist for the treatment of Alzheimer’s Disease. American Society for Experimental Neurotherapeutics Annual Meeting; 2009. Chicago, IL.
   Google Scholar
• Marcos B, Gil-Bea F, Hirst WD, et al. Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release. Eur.J.Neurosci. 2006;24:1299–1306.
   PubMed Web of Science ®Google Scholar
• de Jong IEM, Mørk A. Antagonism of the 5-HT6 receptor - preclinical rationale for the treatment of Alzheimer’s Disease. Neuropharmacology. 2017;125:50–63.
   PubMed Web of Science ®Google Scholar
• Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. NatRevDrug Discov. 2007;6:721–733.
   Google Scholar
• Ruberg M, Ploska A, Javoy-Agid F, et al. Muscarinic binding and choline acetyltransferase activity in parkinsonian subjects with reference to dementia. Brain Res. 1982;232:129–139.
   PubMed Web of Science ®Google Scholar
• Dubois B, Ruberg M, Javoy-Agid F, et al. A subcortico-cortical cholinergic system is affected in Parkinson’s Disease. Brain Res. 1983;288:213–218.
   PubMed Web of Science ®Google Scholar
• Rinne JO, Lönnberg P, Marjamäki P, et al. Brain muscarinic receptor subtypes are differently affected in Alzheimer’s Disease and Parkinson’s Disease. Brain Res. 1989;483:402–406.
   PubMed Web of Science ®Google Scholar
• Ballard C, Piggott M, Johnson M, et al. Delusions associated with elevated muscarinic binding in dementia with Lewy Bodies. Ann.Neurol. 2000;48:868–876.
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Kanel P, Müller MLTM. Molecular imaging of the cholinergic system in Parkinson’s Disease. Int.Rev.Neurobiol. 2018;141:211–250.
   PubMed Web of Science ®Google Scholar
• Colloby SJ, McKeith IG, Burn DJ, et al. Cholinergic and perfusion brain networks in Parkinson Disease dementia. Neurology. 2016;87:178–185.
   PubMed Web of Science ®Google Scholar
• Duvoisin RC. Cholinergic-anticholinergic antagonism in parkinsonism. Arch.Neurol. 1967;17:124–136.
   PubMedGoogle Scholar
• Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol.Ther. 2008;117:232–243.
   PubMed Web of Science ®Google Scholar
• Clader JW, Wang Y. Muscarinic receptor agonists and antagonists in the treatment of Alzheimer’s Disease. Curr.Pharm.Des. 2005;11:3353–3361.
   PubMed Web of Science ®Google Scholar
• Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer Disease. Arch.Neurol. 1997;54:465–473.
   PubMedGoogle Scholar
• Fisher A, Heldman E, Gurwitz D, et al. M1 agonists for the treatment of Alzheimer’s Disease. Novel properties and clinical update. Ann.N.Y.Acad.Sci. 1996;777:189–196.
   PubMed Web of Science ®Google Scholar
• Zoli M, Pistillo F, Gotti C. Diversity of native nicotinic receptor subtypes in mammalian brain. Neuropharmacology. 2015;96:302–311.
   PubMed Web of Science ®Google Scholar
• Quik M, Zhang D, McGregor M, et al. Alpha7 nicotinic receptors as therapeutic targets for Parkinson’s Disease. Biochem.Pharmacol. 2015;97:399–407.
   PubMed Web of Science ®Google Scholar
• Lange KW, Wells FR, Jenner P, et al. Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson’s Disease. J.Neurochem. 1993;60:197–203.
   PubMed Web of Science ®Google Scholar
• Rinne JO, Myllykylä T, Lönnberg P, et al. A postmortem study of brain nicotinic receptors in Parkinson’s and Alzheimer’s Disease. Brain Res. 1991;547:167–170.
   PubMed Web of Science ®Google Scholar
• Whitehouse PJ, Martino AM, Wagster MV, et al. Reductions in [3H]nicotinic acetylcholine binding in Alzheimer’s Disease and Parkinson’s Disease: an autoradiographic study. Neurology. 1988;38:720–723.
   Web of Science ®Google Scholar
• Reid RT, Sabbagh MN, Corey-Bloom J, et al. Nicotinic receptor losses in dementia with Lewy Bodies: comparisons with Alzheimer’s Disease. Neurobiol.Aging. 2000;21:741–746.
   Web of Science ®Google Scholar
• Court JA, Ballard CG, Piggott MA, et al. Visual hallucinations are associated with Lower alpha bungarotoxin binding in dementia with Lewy Bodies. Pharmacol.Biochem.Behav. 2001;70:571–579.
   PubMed Web of Science ®Google Scholar
• Meyer PM, Strecker K, Kendziorra K, et al. Reduced alpha4beta2*-Nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson Disease. Arch.Gen.Psychiatry. 2009;66:866–877.
   Web of Science ®Google Scholar
• Fujita M, Ichise M, Zoghbi SS, et al. Widespread decrease of nicotinic acetylcholine receptors in Parkinson’s Disease. Ann.Neurol. 2006;59:174–177.
   PubMed Web of Science ®Google Scholar
• Colloby SJ, Perry EK, Pakrasi S, et al. Nicotinic 123I-5IA-85380 single photon emission computed tomography as a predictor of cognitive progression in Alzheimer’s Disease and dementia with Lewy Bodies. Am.J.Geriatr.Psychiatry. 2010;18:86–90.
   PubMed Web of Science ®Google Scholar
• Pimlott SL, Piggott M, Owens J, et al. Nicotinic acetylcholine receptor distribution in Alzheimer’s Disease, dementia with Lewy Bodies, Parkinson’s Disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. Neuropsychopharmacology. 2004;29:108–116.
   PubMed Web of Science ®Google Scholar
• Quik M, O’Leary K, Tanner CM. Nicotine and Parkinson’s Disease: implications for therapy. Mov.Disord. 2008;23:1641–1652.
   PubMed Web of Science ®Google Scholar
• Oertel W, Müller H, Schade-Brittinger C, et al. The NIC-PD-study –a randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in Early Parkinson‘s Disease in Germany and N. America. Mov Disord. 2018;33(suppl 2):S159–S160.
   Web of Science ®Google Scholar
• Villafane G, Thiriez C, Audureau E, et al. High-dose transdermal nicotine in Parkinson’s Disease patients: a randomized, open-label, blinded-endpoint evaluation Phase 2 Study. Eur.J.Neurol. 2018;25:120–127.
   PubMed Web of Science ®Google Scholar
• Clemens P, Baron JA, Coffey D, et al. The short-term effect of nicotine chewing gum in patients with Parkinson’s Disease. Psychopharmacology (Berl). 1995;117:253–256.
   PubMed Web of Science ®Google Scholar
• Lieberman A, Lockhart TE, Olson MC, et al. Nicotine bitartrate reduces falls and freezing of gait in Parkinson Disease: a reanalysis. Front.Neurol. 2019;10:424.
   PubMed Web of Science ®Google Scholar
• Kelton MC, Kahn HJ, Conrath CL, et al. The effects of nicotine on Parkinson’s Disease. Brain Cogn. 2000;43:274–282.
   PubMed Web of Science ®Google Scholar
• Lemay S, Chouinard S, Blanchet P, et al. Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson’s Disease. Prog.Neuropsychopharmacol.Biol.Psychiatry. 2004;28:31–39.
   PubMed Web of Science ®Google Scholar
• Newhouse P, Kellar K, Aisen P, et al. Nicotine treatment of mild cognitive impairment: A 6-month double-blind pilot clinical trial. Neurology. 2012;78:91–101.
   PubMed Web of Science ®Google Scholar
• Hukkanen J, Jacob P 3rd, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol.Rev. 2005;57:79–115.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Berg D, Rascol O, et al. A placebo-controlled trial of AQW051 in patients with moderate to severe levodopa-induced dyskinesia. Mov.Disord. 2016;31:1049–1054.
   Web of Science ®Google Scholar
• Parkinson Study Group. Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson Disease. Neurology. 2006;66:408–410.
   Web of Science ®Google Scholar
• Berger-Sweeney J, Stearns NA, Frick KM, et al. Cholinergic basal forebrain is critical for social transmission of food preferences. Hippocampus. 2000;10:729–738.
   PubMed Web of Science ®Google Scholar
• Butt AE, Schultz JA, Arnold LL, et al. Lesions of the rat nucleus basalis magnocellularis disrupt appetitive-to-aversive transfer learning. Integr Physiol Behav Sci. 2003;38:253–271.
   PubMed Web of Science ®Google Scholar
• Chudasama Y. Cholinergic modulation of visual attention and working memory: dissociable effects of basal forebrain 192-IgG-saporin lesions and intraprefrontal infusions of scopolamine. Learn Memory. 2004;11:78–86.
   PubMed Web of Science ®Google Scholar
• Linster C, Garcia PA, Hasselmo ME, et al. Selective loss of cholinergic neurons projecting to the olfactory system increases perceptual generalization between similar, but not dissimilar, odorants. Behav.Neurosci. 2001;115:826–833.
   PubMed Web of Science ®Google Scholar
• Kurosawa M, Sato A, Sato Y. Stimulation of the nucleus basalis of meynert increases acetylcholine release in the cerebral cortex in rats. Neurosci.Lett. 1989;98:45–50.
   PubMed Web of Science ®Google Scholar
• McLin DE, Miasnikov AA, Weinberger NM. Induction of behavioral associative memory by stimulation of the nucleus basalis. Proc.Natl.Acad.Sci.U.S.A. 2002;99:4002–4007.
   PubMed Web of Science ®Google Scholar
• Bakin JS, Weinberger NM. Induction of a physiological memory in the cerebral cortex by stimulation of the nucleus basalis. Proc Nat Acad Sci. 1996;93:11219–11224.
   PubMed Web of Science ®Google Scholar
• Kilgard MP, Vazquez JL, Engineer ND, et al. Experience dependent plasticity alters cortical synchronization. Hear.Res. 2007;229:171–179.
   PubMed Web of Science ®Google Scholar
• Weinberger NM, Miasnikov AA, Chen JC. Sensory memory consolidation observed: increased specificity of detail over days. Neurobiol.Learn.Mem. 2009;91:273–286.
   Web of Science ®Google Scholar
• Miasnikov AA, Chen JC, Weinberger NM. Consolidation and long-term retention of an implanted behavioral memory. Neurobiol.Learn.Mem. 2011;95:286–295.
   PubMed Web of Science ®Google Scholar
• Weinberger NM, Miasnikov AA, Bieszczad KM, et al. Gamma band plasticity in sensory cortex is a signature of the strongest memory rather than memory of the training stimulus. Neurobiol.Learn.Mem. 2013;104:49–63.
   PubMed Web of Science ®Google Scholar
• Montero-Pastor A, Vale-Martínez A, Guillazo-Blanch G, et al. Effects of electrical stimulation of the nucleus basalis on two-way active avoidance acquisition, retention, and retrieval. BehavBrain Res. 2004;154:41–54.
   PubMed Web of Science ®Google Scholar
• Freund H, Kuhn J, Lenartz D, et al. Cognitive functions in a patient with parkinson-dementia syndrome undergoing deep brain stimulation. Arch.Neurol. 2009;66:781–785.
   PubMedGoogle Scholar
• Barnikol TT, Pawelczyk NBA, Barnikol UB, et al. Changes in apraxia after deep brain stimulation of the nucleus basalis meynert in a patient with parkinson dementia syndrome. Mov Disord. 2010;25:1519–1520.
   PubMedGoogle Scholar
• Slomine BS, Silverstein FS, Christensen J, et al. Neuropsychological outcomes of Children 1 Year after pediatric cardiac arrest: secondary analysis of 2 randomized clinical Trials. JAMA Neurol. 2018;75:1502–1510.
   PubMed Web of Science ®Google Scholar
• Kuhn J, Hardenacke K, Lenartz D, et al. Deep brain stimulation of the nucleus basalis of meynert in Alzheimer’s Dementia. Mol.Psychiatry. 2015;20:353–360.
   PubMed Web of Science ®Google Scholar
• Thevathasan W, Pogosyan A, Hyam JA, et al. Alpha oscillations in the pedunculopontine nucleus correlate with gait performance in parkinsonism. Brain. 2012;135:148–160.
   Web of Science ®Google Scholar
• Thevathasan W, Debu B, Aziz T, et al. Pedunculopontine nucleus deep brain stimulation in Parkinson’s Disease: a clinical review. Mov Disord. 2018;33:10–20.
   PubMed Web of Science ®Google Scholar
• Zrinzo L, Zrinzo LV, Hariz M. The peripeduncular nucleus: a novel target for deep brain stimulation? Neuroreport. 2007;18:1301–1302.
   Web of Science ®Google Scholar
• Yelnik J. PPN or PPD, what is the target for deep brain stimulation in Parkinson’s Disease? Brain. 2007;130:e79–e79.
   PubMed Web of Science ®Google Scholar
• Jenkinson N, Nandi D, Muthusamy K, et al. Anatomy, physiology, and pathophysiology of the pedunculopontine nucleus. Mov.Disord. 2009;24:319–328.
   PubMed Web of Science ®Google Scholar
• Garcia-Rill E, Houser CR, Skinner RD, et al. Locomotion-inducing sites in the vicinity of the pedunculopontine nucleus. Brain ResBull. 1987;18:731–738.
   PubMed Web of Science ®Google Scholar
• Nandi D, Aziz TZ, Giladi N, et al. Reversal of akinesia in experimental parkinsonism by GABA antagonist microinjections in the pedunculopontine nucleus. Brain. 2002;125:2418–2430.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang Y, Zhang X, et al. Deep brain stimulation of pedunculopontine nucleus for postural instability and gait disorder after Parkinson Disease: a meta-analysis of individual patient data. World Neurosurg. 2017;102:72–78.
   PubMed Web of Science ®Google Scholar
• Plaha P, Gill SS. Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson’s Disease. Neuroreport. 2005;16:1883–1887.
   PubMed Web of Science ®Google Scholar
• Ferraye MU, Debû B, Fraix V, et al. Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson’s Disease. Brain. 2010;133:205–214.
   PubMed Web of Science ®Google Scholar
• Moro E, Hamani C, Poon Y, et al. Unilateral pedunculopontine stimulation improves falls in Parkinson’s Disease. Brain. 2010;133:215–224.
   Web of Science ®Google Scholar
• Strafella AP, Lozano AM, Ballanger B, et al. rCBF changes associated with PPN stimulation in a patient with Parkinson’s Disease: A PET study. Mov Disord. 2008;23:1051–1054.
   PubMed Web of Science ®Google Scholar
• Thevathasan W, Coyne TJ, Hyam JA, et al. Pedunculopontine nucleus stimulation improves gait freezing in Parkinson Disease. Neurosurgery. 2011;69:1248–53; discussion 1254. discussion 1254.
   PubMed Web of Science ®Google Scholar
• Mestre TA, Sidiropoulos C, Hamani C, et al. Long-term double-blinded unilateral pedunculopontine area stimulation in Parkinson’s Disease. Mov Disord. 2016;31:1570–1574.
   PubMed Web of Science ®Google Scholar
• Thevathasan W, Cole MH, Graepel CL, et al. A spatiotemporal analysis of gait freezing and the impact of pedunculopontine nucleus stimulation. Brain. 2012;135:1446–1454.
   Web of Science ®Google Scholar
• Thevathasan W, Silburn PA, Brooker H, et al. The impact of low-frequency stimulation of the pedunculopontine nucleus region on reaction time in parkinsonism. J Neurol Neurosurg. 2010;81:1099–1104.
   PubMed Web of Science ®Google Scholar
• Welter M, Demain A, Ewenczyk C, et al. PPNa-DBS for gait and balance disorders in Parkinson’s Disease: a double-blind, randomised study. J.Neurol. 2015;262:1515–1525.
   PubMed Web of Science ®Google Scholar
• Stefani A, Lozano AM, Peppe A, et al. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson’s Disease. Brain. 2007;130:1596–1607.
   PubMed Web of Science ®Google Scholar
• Nosko D, Ferraye MU, Fraix V, et al. Low-frequency versus high-frequency stimulation of the pedunculopontine nucleus area in Parkinson’s Disease: a randomised controlled trial. J Neurol Neurosurg. 2015;86:674–679.
   PubMed Web of Science ®Google Scholar
• Khan S, Mooney L, Plaha P, et al. Outcomes from stimulation of the caudal zona incerta and pedunculopontine nucleus in patients with Parkinson’s Disease. Br.J.Neurosurg. 2011;25:273–280.
   Web of Science ®Google Scholar
• Khan S, Gill SS, Mooney L, et al. Combined pedunculopontine-subthalamic stimulation in Parkinson Disease. Neurology. 2012;78:1090–1095.
   Web of Science ®Google Scholar
• Thevathasan W, Pogosyan A, Hyam JA, et al. A block to pre-prepared movement in gait freezing, relieved by pedunculopontine nucleus stimulation. Brain. 2011;134:2085–2095.
   PubMed Web of Science ®Google Scholar
• Fischer J, Schwiecker K, Bittner V, et al. Modulation of attentional processing by deep brain stimulation of the pedunculopontine nucleus region in patients with Parkinsonian Disorders. Neuropsychology. 2015;29:632–637.
   PubMed Web of Science ®Google Scholar
• Duncan T, Valenzuela M. Alzheimer’s disease, dementia, and stem cell therapy. Stem Cell Res Ther. 2017;8:111.
   PubMed Web of Science ®Google Scholar
• Bissonnette CJ, Lyass L, Bhattacharyya BJ, et al. The controlled generation of functional basal forebrain cholinergic neurons from human embryonic stem cells. Stem Cells. 2011;29:802–811.
   PubMed Web of Science ®Google Scholar
• Moghadam FH, Alaie H, Karbalaie K, et al. Transplantation of primed or unprimed mouse embryonic stem cell-derived neural precursor cells improves cognitive function in alzheimerian rats. Differentiation. 2009;78:59–68. Special Issue on Stem Cells.
   PubMed Web of Science ®Google Scholar
• Wang H, Hu Y-C, Markoulaki S, et al. Neurophysiological biomarkers for Lewy body dementias. Nat.Biotechnol. 2016;127:349–359.
   Google Scholar
• Fong C, Gauthaman K, Bongso A. Teratomas from pluripotent stem cells: a clinical hurdle. J.Cell.Biochem. 2010;111:769–781.
   Web of Science ®Google Scholar
• Goldberg NRS, Marsh SE, Ochaba J, et al. Human neural progenitor transplantation rescues behavior and reduces α-synuclein in a transgenic model of dementia with Lewy Bodies. Stem Cells Transl Med. 2017;6:1477–1490.
   PubMed Web of Science ®Google Scholar
• McGinley LM, Kashlan ON, Bruno ES, et al. Human neural stem cell transplantation improves cognition in a murine model of Alzheimer’s Disease. Sci Rep. 2018;8:14776.
   PubMed Web of Science ®Google Scholar
• Xuan AG, Luo M, Ji WD, et al. Effects of engrafted neural stem cells in Alzheimer’s Disease rats. Neurosci.Lett. 2009;450:167–171.
   PubMed Web of Science ®Google Scholar
• Hossini AM, Megges M, Prigione A, et al. Induced pluripotent stem cell-derived neuronal cells from a sporadic Alzheimer’s Disease donor as a model for investigating AD-Associated Gene regulatory networks. BMC Genomics. 2015;16:84.
   PubMed Web of Science ®Google Scholar
• Muratore CR, Rice HC, Srikanth P, et al. The familial Alzheimer’s Disease APPV717I mutation alters APP processing and tau expression in iPSC-derived neurons. Hum.Mol.Genet. 2014;23:3523–3536.
   PubMed Web of Science ®Google Scholar
• Balez R, Steiner N, Engel M, et al. Neuroprotective effects of apigenin against inflammation, neuronal excitability and apoptosis in an induced pluripotent stem cell model of Alzheimer’s Disease. Sci Rep. 2016;6:31450.
   PubMed Web of Science ®Google Scholar
• Chakari-Khiavi F, Dolati S, Chakari-Khiavi A, et al. Prospects for the application of mesenchymal stem cells in Alzheimer’s Disease treatment. Life Sci. 2019;231:116564.
   PubMed Web of Science ®Google Scholar
• Oh SH, Kim HN, Park H, et al. Mesenchymal stem cells increase hippocampal neurogenesis and neuronal differentiation by enhancing the wnt signaling pathway in an Alzheimer’s Disease model. Cell Transplant. 2015;24:1097–1109.
   Web of Science ®Google Scholar
• Ra JC, Shin IS, Kim SH, et al. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev. 2011;20:1297–1308.
   PubMed Web of Science ®Google Scholar
• Lee J, Kuroda S, Shichinohe H, et al. Migration and differentiation of nuclear fluorescence-labeled bone marrow stromal cells after transplantation into cerebral infarct and spinal cord injury in mice. Neuropathology. 2003;23:169–180.
   PubMed Web of Science ®Google Scholar
• Park H, Oh J, Shim G, et al. In vivo neuronal gene editing via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer’s Disease. Nat.Neurosci. 2019;22:524–528.
   PubMed Web of Science ®Google Scholar
• Jiang S, Wen N, Li Z, et al.,, . Integrative system biology analyses of CRISPR-Edited iPSC-derived neurons and human brains reveal deficiencies of presynaptic signaling in FTLD and PSP. Transl Psychiatry. 2018;8:265.
   PubMed Web of Science ®Google Scholar
• García-León JA, Cabrera-Socorro A, Eggermont K, et al. Generation of a human induced pluripotent stem cell-based model for tauopathies combining three microtubule-associated protein TAU mutations which displays several phenotypes linked to neurodegeneration. Alzheimers Dement. 2018;14:1261–1280.
   PubMed Web of Science ®Google Scholar
• Domenico AD, Carola G, Calatayud C, et al. Patient-specific iPSC-derived astrocytes contribute to non-cell-autonomous neurodegeneration in Parkinson’s Disease. Stem Cell Reports. 2019;12:213–229.
   PubMed Web of Science ®Google Scholar